Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study - Munich 2006

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

International Congresses Munich 2006

Established and experimental therapies for allergic asthma

Chair(s): D. Ukena (Bremen, Germany), L. Bjermer (Lund, Sweden)

Session type: Thematic Poster Session

Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study

N. Bergmann, M. Foerster, A. Reissig, C. Kroegel (Jena, Germany)

EVENTS HOME

Limited Access

Please log in to myERS to view this content.

Don't have a myERS account? Register

Note: consult the ERS Respiratory Channel access rights page for more details.

CDN Connection Issue

The ERS International Congress 2006, Munich

Limited Access

#{title}